Biological markers in the diagnosis and treatment of ALS. (Q31389611)

1 July 2017

1 reference

title

Biological markers in the diagnosis and treatment of ALS. (English)

1 reference

amyotrophic lateral sclerosis

1 July 2017

main subject

1 reference

3

Cashman NR

1 reference

1 July 2017

Kalra S

1

1 reference

1 July 2017

Arnold DL

series ordinal

2

1 reference

1 July 2017

publication date

1 June 1999

1 reference

Journal of the Neurological Sciences

1 July 2017

published in

1 reference

1 July 2017

volume

165 Suppl 1

1 reference

1 July 2017

page(s)

S27-32

1 reference

Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?

1 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

7 January 2021

Excitotoxicity in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Muscarinic, N-methyl-D-aspartate (NMDA) and benzodiazepine receptor binding sites in cortical membranes from amyotrophic lateral sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Induction of the immediate early gene c-jun in human spinal cord in amyotrophic lateral sclerosis with concomitant loss of NMDA receptor NR-1 and glycine transporter mRNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Comparison of single motor unit responses to transcranial magnetic and peroneal nerve stimulation in the tibialis anterior muscle of patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Toxic models of upper motor neuron disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

The neurotoxin, beta-N-methylamino-L-alanine (BMAA) interacts with the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Mutant CuZn superoxide dismutase in motor neuron disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

A comparison of three measures of disease progression in ALS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

A rating scale for amyotrophic lateral sclerosis: description and preliminary experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Cortical projections to spinal motoneurons: changes with aging and amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Transcranial magnetic stimulation as a diagnostic and prognostic test in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Focal signal-intensity variations in the posterior internal capsule: normal MR findings and distinction from pathologic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

MRI and SPECT findings in amyotrophic lateral sclerosis. Demonstration of upper motor neurone involvement by clinical neuroimaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Reduced isotope uptake restricted to the motor area in patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Synthesis of N-acetyl-l-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Effects of hypernatremia on organic brain osmoles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Brief report: organic osmolytes in the brain of an infant with hypernatremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

A relationship of N-acetylaspartate biosynthesis to neuronal protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Decreased brain N-acetylaspartate in Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Reversible decreases in N-acetylaspartate after acute brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Effectiveness of revascularization surgery evaluated by proton magnetic resonance spectroscopy and single photon emission computed tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Mitochondrial dysfunction is a primary event in glutamate neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

The pharmacology and mechanism of action of riluzole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunohistochemical localization of N-acetylaspartate in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900023-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-510X(99)00023-4

1 reference

1 July 2017

1 reference